Plant Name: Aglaia perviridis
Taxonomic Information:
Plant ID: NPO4720
Plant Latin Name: Aglaia perviridis
Taxonomy Genus: Aglaia
Taxonomy Family: Meliaceae
Plant External Links:
NCBI TaxonomyDB:
306512
Plant-of-the-World-Online:
577254-1
Used in Medicines:
Unknown.
Geographical Distribution:
India; Vietnam; China; Bangladesh; Thailand
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CNR2; | |
| EIF4A1; GFER; HSD17B10; ALDH1A1; | |
| CA7; CA12; CA9; | |
| HMGCR; | |
| CASP7; CASP1; | |
| RELA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | EIF4A1 | Eukaryotic initiation factor 4A-I | P60842 | CHEMBL2052028 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Oxidoreductase | HMGCR | HMG-CoA reductase | P04035 | CHEMBL402 |
| Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
| Transcription Factor | RELA | Nuclear factor NF-kappa-B p65 subunit | Q04206 | CHEMBL5533 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.753E-09 | 5.053E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.576E-08 | 1.734E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.582E-08 | 1.734E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.952E-07 | 4.592E-04 | ALDH1A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GFER, HMGCR, HSD17B10 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.109E-07 | 4.592E-04 | CA12, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.146E-07 | 1.217E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.175E-07 | 1.318E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 8.836E-07 | 1.318E-03 | CA9, CASP1, CASP7, CYP1A1, CYP1A2, CYP1B1, RELA |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 9.686E-07 | 1.318E-03 | CA9, CASP1, CNR2, CYP1A1, CYP1B1, HMGCR, RELA |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.278E-06 | 1.637E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, HMGCR |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 2.245E-06 | 2.444E-03 | CASP1, CNR2, CYP1A1, CYP1A2, RELA |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.274E-06 | 2.971E-03 | CA12, CA7, CA9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.148E-06 | 2.971E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.856E-06 | 3.343E-03 | CYP1A1, CYP1A2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.049E-06 | 4.704E-03 | CA12, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.636E-06 | 5.481E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 1.377E-05 | 8.102E-03 | CNR2, CYP1A1, CYP1B1, HMGCR, RELA |
| BP | GO:0050896; response to stimulus | GO:0007584; response to nutrient | 1.601E-05 | 8.713E-03 | CASP1, CYP1A1, HMGCR, RELA |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 1.796E-05 | 9.538E-03 | CYP1A1, CYP1A2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.129E-07 | 8.015E-06 | CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.076E-06 | 9.647E-05 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 8.047E-06 | 1.428E-04 | CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.837E-07 | 1.007E-05 | CA12, CA7, CA9 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 1.074E-05 | 1.526E-04 | CASP7, CASP1, RELA |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.780E-05 | 2.107E-04 | CYP1A2, ALDH1A1, CYP1A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.525E-05 | 2.430E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 2.739E-05 | 2.430E-04 | CASP7, CASP1, RELA |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.579E-05 | 2.824E-04 | CYP1A2, CYP1A1, CYP1B1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.608E-04 | 1.851E-03 | CYP1A2, ALDH1A1, CYP1A1, HMGCR, CYP19A1, HSD17B10 |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 9.334E-04 | 6.025E-03 | CASP1, RELA |
| 09150 Organismal Systems | 09151 Immune system | hsa04623 | Cytosolic DNA-sensing pathway | 1.175E-03 | 6.953E-03 | CASP1, RELA |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | CNR2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR2; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | CNR2; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CNR2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA9; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR2; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
